- $30.59m
- $20.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.29 | ||
| Price to Tang. Book | 3.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -265.75% | ||
| Return on Equity | -3159.09% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Directors
- Michael Hoffman NEC (70)
- Maria Maccecchini PRE (70)
- Jeffrey McGroarty CFO (51)
- Claudine Bruck IND (66)
- Reid McCarthy IND (67)
- Mark White IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 29th, 2008
- Public Since
- January 29th, 2020
- No. of Shareholders
- 23
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 19,486,231
- Address
- 101 LINDENWOOD DRIVE, SUITE 225, MALVERN, 19355
- Web
- https://www.annovisbio.com/
- Phone
- +1 4848753192
- Contact
- Kevin Gardner
- Auditors
- Ernst & Young LLP
Upcoming Events for ANVS
Annovis Bio Inc Annual Shareholders Meeting
Q2 2025 Annovis Bio Inc Earnings Release
Q2 2025 Annovis Bio Inc Earnings Release
Similar to ANVS
ADC Therapeutics SA
New York Stock Exchange
Alto Neuroscience
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Aurion Biotech
New York Stock Exchange
Biohaven
New York Stock Exchange
FAQ
What is the Annovis Bio share price?
As of Today at 19:15 UTC, shares in Annovis Bio are trading at $1.57. This share price information is delayed by 15 minutes.
How has the Annovis Bio share price performed this year?
Shares in Annovis Bio last closed at $1.57 and the price had moved by -88.46% over the past 365 days. In terms of relative price strength the Annovis Bio share price has underperformed the S&P500 Index by -89.34% over the past year.
What are the analyst and broker recommendations for Annovis Bio?
The overall consensus recommendation for Annovis Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Annovis Bio dividend yield?
Annovis Bio does not currently pay a dividend.
Does Annovis Bio pay a dividend?
Annovis Bio does not currently pay a dividend.
When does Annovis Bio next pay dividends?
Annovis Bio does not currently pay a dividend.
How do I buy Annovis Bio shares?
To buy shares in Annovis Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Annovis Bio?
As of the previous close price of $1.57, shares in Annovis Bio had a market capitalisation of $30.59m.
Where are Annovis Bio shares listed?
Here are the trading details for Annovis Bio:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ANVS
What kind of share is Annovis Bio?
Based on an overall assessment of its quality, value and momentum Annovis Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Annovis Bio share price forecast for 2025?
The analyst consensus target price for shares in Annovis Bio is $31.20. That is 1887.26% above the last closing price of $1.57.
Analysts covering Annovis Bio currently have a consensus Earnings Per Share (EPS) forecast of -$1.80 for the next financial year.
Find out moreWhat is the trend in the Annovis Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Annovis Bio. Over the past six months, its share price has underperformed the S&P500 Index by -83.23%.
As of the last closing price of $1.57, shares in Annovis Bio were trading -73.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Annovis Bio PE Ratio?
The Annovis Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Annovis Bio?
Annovis Bio's management team is headed by:
- Michael Hoffman - NEC
- Maria Maccecchini - PRE
- Jeffrey McGroarty - CFO
- Claudine Bruck - IND
- Reid McCarthy - IND
- Mark White - IND